Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7306016 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL3706077 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL12525029 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL12524998 | 1.00 | CYP2C9 (0.42) | CYP2C9CYP2C19SMN1; SMN2GRM5GBA1 | |
| SCHEMBL14980914 | 0.82 | SMN1; SMN2 (0.38) | CYP2C9CYP2C19SMN1; SMN2GBA1CA2 | |
| SCHEMBL23841973 | 0.80 | CYP2C9 (0.41) | CYP2C9CYP2C19CA2GAAALDH1A1 | |
| SCHEMBL135940 | 0.77 | CA2 (0.40) | CYP2C9CYP2C19SMN1; SMN2CA2GAA | |
| SCHEMBL1443275 | 0.71 | GRM5 (0.66) | SMN1; SMN2GRM5CA2 | |
| SCHEMBL14508491 | 0.71 | GRM5 (0.66) | SMN1; SMN2GRM5CA2 | |
| SCHEMBL2798313 | 0.71 | GRM5 (0.66) | SMN1; SMN2GRM5CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 170 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545685-B2 | Dispiropyrrolidine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-02-10 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-12-26 | — | — | US | disclosed |
| EP-4447959-A1 | METHODS OF TREATING CANCER | Kymera Therapeutics, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118574613-A | Methods of treating cancer | 凯麦拉医疗公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20240246989-A1 | DISPIROPYRROLIDINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-25 | — | — | US | disclosed |
| US-11932624-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-7759383-B2 | INHIBITORS OF MURINE DOUBLE MINUTE-2(MDM2) SUCH AS (2'R,3'S,4'R,5'R)6-CHLORO-4'-2,2-DIMETHYL-PROPYL-2'-(2,2-DIMETHYL-PROPYL)-2-OXO-1,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXYLIC ACID(3-MORPHOLIN-4-YL-PROPYL)-AMIDE, USED FOR INDUCING APOPTOSIS AND CELL CYCLE ARREST; ANTIPROLIFERATIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759383-B2 | INHIBITORS OF MURINE DOUBLE MINUTE-2(MDM2) SUCH AS (2'R,3'S,4'R,5'R)6-CHLORO-4'-2,2-DIMETHYL-PROPYL-2'-(2,2-DIMETHYL-PROPYL)-2-OXO-1,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXYLIC ACID(3-MORPHOLIN-4-YL-PROPYL)-AMIDE, USED FOR INDUCING APOPTOSIS AND CELL CYCLE ARREST; ANTIPROLIFERATIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759383-B2 | INHIBITORS OF MURINE DOUBLE MINUTE-2(MDM2) SUCH AS (2'R,3'S,4'R,5'R)6-CHLORO-4'-2,2-DIMETHYL-PROPYL-2'-(2,2-DIMETHYL-PROPYL)-2-OXO-1,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXYLIC ACID(3-MORPHOLIN-4-YL-PROPYL)-AMIDE, USED FOR INDUCING APOPTOSIS AND CELL CYCLE ARREST; ANTIPROLIFERATIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-07-20 | — | — | US | disclosed |
| US-7737174-B2 | Indole inhibitors of MDM2 and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-06-15 | — | — | US | disclosed |
| US-7737174-B2 | Indole inhibitors of MDM2 and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-06-15 | — | — | US | disclosed |
| US-20080125430-A1 | NEW SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-05-29 | — | — | US | disclosed |
| US-20080125430-A1 | NEW SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-05-29 | — | — | US | disclosed |
| WO-2008036168-A2 | NEW SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-03-27 | — | — | WO | disclosed |
| US-20060211757-A1 | INHIBITORS OF MURINE DOUBLE MINUTE-2(MDM2) SUCH AS (2'R,3'S,4'R,5'R)6-CHLORO-4'-2,2-DIMETHYL-PROPYL-2'-(2,2-DIMETHYL-PROPYL)-2-OXO-1,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXYLIC ACID(3-MORPHOLIN-4-YL-PROPYL)-AMIDE, USED FOR INDUCING APOPTOSIS AND CELL CYCLE ARREST; ANTIPROLIFERATIVE AGENTS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-09-21 | — | — | US | disclosed |
| WO-2006091646-A2 | SMALL MOLECULE INHIBITORS OF MDM2 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | CYP2C9 2267/4885CYP2C19 2181/4885SMN1; SMN2 3149/4885 |
| US-12545685-B2 | Dispiropyrrolidine derivatives | TP53, MDM2, TP53BP1 | CYP2C9 3770/4885CYP2C19 4436/4885SMN1; SMN2 4675/4885 |
| US-20240424110-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, USP2, MYCBP2 | CYP2C9 3976/4885CYP2C19 4244/4885SMN1; SMN2 2413/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | CYP2C9 2559/4885CYP2C19 2475/4885SMN1; SMN2 737/4885 |
| US-20080125430-A1 | NEW SMALL MOLECULE INHIBITORS OF MDM2 AND THE USES THEREOF | TP53, MDM2, CDKN1A | CYP2C9 4660/4885CYP2C19 4632/4885SMN1; SMN2 3993/4885 |
| US-11932624-B2 | MDM2 degraders and uses thereof | MDM2, TP53, MDM4 | CYP2C9 2267/4885CYP2C19 2181/4885SMN1; SMN2 3149/4885 |
| US-20240246989-A1 | DISPIROPYRROLIDINE DERIVATIVES | MDM2, TP53, TP53BP1 | CYP2C9 2318/4885CYP2C19 2708/4885SMN1; SMN2 4677/4885 |
| US-20060211757-A1 | INHIBITORS OF MURINE DOUBLE MINUTE-2(MDM2) SUCH AS (2'R,3'S,4'R,5'R)6-CHLORO-4'-2,2-DIMETHYL-PROPYL-2'-(2,2-DIMETHYL-PROPYL)-2-OXO-1,2-DIHYDRO-SPIRO[INDOLE-3,3'-PYRROLIDINE]-5'-CARBOXYLIC ACID(3-MORPHOLIN-4-YL-PROPYL)-AMIDE, USED FOR INDUCING APOPTOSIS AND CELL CYCLE ARREST; ANTIPROLIFERATIVE AGENTS | SKP2, MDM2, CCAR2 | CYP2C9 3945/4885CYP2C19 4412/4885SMN1; SMN2 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.